Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro

Androgenic disorders of female skin such as hirsutism, acne and alopecia are etiologically caused by androgen excess. Skin 5α-reductase activity is a major factor influencing the manifestation of endogenous androgen excess in women. Oral contraceptives have proven useful for the treatment of androge...

Full description

Saved in:
Bibliographic Details
Published in:Gynecological endocrinology 2000, Vol.14 (4), p.223-230
Main Authors: Rabe, T., Kowald, A., Ortmann, J., Rehberger-Schneider, S.
Format: Article
Language:English
Subjects:
3-Oxo-5-alpha-Steroid 4-Dehydrogenase - drug effects
5α-Reductase
Adolescent
Adult
Biological and medical sciences
Birth control
Contraceptives, Oral - pharmacology
Dose-Response Relationship, Drug
Female
Gynecology. Andrology. Obstetrics
Hormonal contraception
Humans
Hyperandrogenism - prevention & control
Medical sciences
Nandrolone - analogs & derivatives
Nandrolone - pharmacology
Norgestrel - analogs & derivatives
Norgestrel - pharmacology
Oral Contraceptive
Progestin
Progestins - pharmacology
Receptors, Androgen - drug effects
Skin - enzymology
Skin - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Androgenic disorders of female skin such as hirsutism, acne and alopecia are etiologically caused by androgen excess. Skin 5α-reductase activity is a major factor influencing the manifestation of endogenous androgen excess in women. Oral contraceptives have proven useful for the treatment of androgen disorders of the skin. The mechanisms of action by which oral contraceptives correct skin androgen levels may include inhibition of 5α-reductase and androgen receptor activity. We investigated the inhibitory effect of oral contraceptive progestins and ethinyl estradiol on skin 5α-reductase and their influence on androgen receptor activity and affinity, using three different in vitro assay systems. It was shown that norgestimate blocked 5α-reductase activity with an IC50 value of 10 μM, followed by levonorgestrel (IC50 52 μM), dienogest (IC50 55 μM), cyproterone acetate (IC50 87 μM) and gestodene (IC50 98 μM). To determine the full androgenic potential of the progestins, androgen receptor binding affinities and activation potentials were determined. The progestins norgestimate and dienogest in particular combined 5α-reductase inhibition with minimal androgenic potential. These data demonstrate that the progestins norgestimate and dienogest might help in the treatment of clinical hyperandrogeny in women.
ISSN:0951-3590
1473-0766
DOI:10.3109/09513590009167685